{"id":"https://openalex.org/W2890848874","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e18553","title":"Survival outcomes in patients with chronic phase chronic myeloid leukemia (CP-CML) receiving third- or subsequent line (3L) treatment prior to the availability of ponatinib.","display_name":"Survival outcomes in patients with chronic phase chronic myeloid leukemia (CP-CML) receiving third- or subsequent line (3L) treatment prior to the availability of ponatinib.","publication_year":2017,"publication_date":"2017-05-20","ids":{"openalex":"https://openalex.org/W2890848874","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e18553","mag":"2890848874"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2017.35.15_suppl.e18553","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e18553","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.e18553","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5086133015","display_name":"Daniel Stellato","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122455","display_name":"Policy Analysis (United States)","ror":"https://ror.org/02jxrxr40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel R Stellato","raw_affiliation_strings":["Policy Analysis Inc. (PAI), Brookline, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Policy Analysis Inc. (PAI), Brookline, MA;","institution_ids":["https://openalex.org/I4210122455"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039857883","display_name":"Lisa J. McGarry","orcid":"https://orcid.org/0000-0003-3454-9184","observed_orcids":["https://orcid.org/0000-0003-3454-9184"]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa McGarry","raw_affiliation_strings":["ARIAD Pharmaceuticals, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ARIAD Pharmaceuticals, Cambridge, MA;","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060404340","display_name":"Hui Huang","orcid":"https://orcid.org/0000-0001-8599-7441","observed_orcids":["https://orcid.org/0000-0001-8599-7441"]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hui Huang","raw_affiliation_strings":["ARIAD Pharmaceuticals, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ARIAD Pharmaceuticals, Cambridge, MA;","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001453269","display_name":"Shaina Hastings","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122455","display_name":"Policy Analysis (United States)","ror":"https://ror.org/02jxrxr40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shaina Hastings","raw_affiliation_strings":["Policy Analysis Inc. (PAI), Brookline, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Policy Analysis Inc. (PAI), Brookline, MA;","institution_ids":["https://openalex.org/I4210122455"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001188908","display_name":"Thomas E. Delea","orcid":"https://orcid.org/0000-0001-5493-1925","observed_orcids":["https://orcid.org/0000-0001-5493-1925"]},"institutions":[{"id":"https://openalex.org/I4210122455","display_name":"Policy Analysis (United States)","ror":"https://ror.org/02jxrxr40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas E. Delea","raw_affiliation_strings":["Policy Analysis Inc. (PAI), Brookline, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Policy Analysis Inc. (PAI), Brookline, MA;","institution_ids":["https://openalex.org/I4210122455"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"35","issue":"15_suppl","first_page":"e18553","last_page":"e18553"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-phase-cml","display_name":"chronic phase CML","score":0.9509999752044678},{"id":"https://openalex.org/keywords/third-line-therapy","display_name":"third-line therapy","score":0.8529999852180481},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7799999713897705},{"id":"https://openalex.org/keywords/ponatinib","display_name":"ponatinib","score":0.8790000081062317},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9190000295639038},{"id":"https://openalex.org/keywords/nilotinib","display_name":"nilotinib","score":0.9539999961853027},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":1.0},{"id":"https://openalex.org/keywords/pace-trial","display_name":"PACE trial","score":0.8489999771118164},{"id":"https://openalex.org/keywords/bcr-abl","display_name":"BCR-ABL","score":0.7049999833106995},{"id":"https://openalex.org/keywords/philadelphia-chromosome-positive-acute-lymphoblastic-leukemia","display_name":"Philadelphia chromosome-positive acute lymphoblastic leukemia","score":0.7509999871253967},{"id":"https://openalex.org/keywords/t315i-mutation","display_name":"T315I mutation","score":0.8119999766349792}],"concepts":[{"id":"https://openalex.org/C2780381907","wikidata":"https://www.wikidata.org/wiki/Q198728","display_name":"Ponatinib","level":5,"score":0.9775388836860657},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9022653102874756},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.7172082662582397},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6203417778015137},{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.6111252307891846},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5123971104621887},{"id":"https://openalex.org/C2778208673","wikidata":"https://www.wikidata.org/wiki/Q894611","display_name":"Bosutinib","level":5,"score":0.4259629249572754},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.41966119408607483},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.41193145513534546},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.28518182039260864}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2017.35.15_suppl.e18553","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e18553","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.e18553","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2751737227","https://openalex.org/W3216423455","https://openalex.org/W2571942489","https://openalex.org/W4317717496","https://openalex.org/W2949953124","https://openalex.org/W3114138495","https://openalex.org/W2904333230","https://openalex.org/W2218351011","https://openalex.org/W4290841268","https://openalex.org/W4312007572"],"abstract_inverted_index":{"e18553":[0],"Background:":[1],"PACE":[2,46,270],"was":[3,54,85,231],"a":[4,11,104],"phase":[5],"2":[6,205],"single-arm":[7],"trial":[8],"of":[9,74,117,127,222,239],"ponatinib,":[10,228],"3rd-generation":[12],"tyrosine":[13],"kinase":[14],"inhibitor":[15],"(TKI),":[16],"in":[17,45,90,216,244,264,269],"449":[18],"highly-refractory":[19],"patients":[20,44,69,91,180,245,263],"with":[21,92,112,227,246],"CML":[22],"or":[23,31,172],"Philadelphia-chromosome":[24],"positive":[25],"(Ph+)":[26],"acute":[27],"lymphocytic":[28],"leukemia":[29],"(ALL)":[30],"who":[32],"had":[33],"the":[34,72,211,217,237],"BCR-ABL":[35],"T315I":[36],"mutation.":[37],"Overall":[38],"survival":[39,65,133,144,152,176,267,276],"(OS)":[40],"for":[41,66,143,175,178,188,192,289],"3L":[42,67,95,182,249],"CP-CML":[43,68,93,179,247],"at":[47,203],"1,":[48,204],"2,":[49],"3":[50,199,207],"and":[51,61,124,131,156,206,287],"4":[52],"years":[53,208],"estimated":[55,274],"to":[56,71,87,98,252,255,279,285],"be":[57,256],"91%,":[58],"83%,":[59],"80%,":[60],"79%,":[62],"respectively.":[63],"Expected":[64],"prior":[70,97,251,278],"availability":[73],"ponatinib":[75,253],"has":[76],"not":[77],"been":[78],"documented.":[79],"Methods:":[80],"A":[81],"systematic":[82],"literature":[83],"review":[84,105],"conducted":[86],"estimate":[88],"OS":[89,189,202,223],"receiving":[94,181,248],"treatment":[96,183,226,250],"ponatinib.":[99,185,280],"Studies":[100],"were":[101,134,146,166,190],"identified":[102,114,167],"from":[103,115,136,148,224],"by":[106],"Lipton":[107],"et":[108],"al.":[109],"(2015),":[110],"updated":[111],"studies":[113,163],"searches":[116],"electronic":[118],"databases":[119,126],"(MEDLINE,":[120],"EMBASE,":[121],"Cochrane":[122],"Libraries)":[123],"abstract":[125],"key":[128],"conferences.":[129],"Landmark":[130],"median":[132],"extracted":[135],"study":[137,230],"reports.":[138],"Pseudo-individual":[139],"patient":[140],"data":[141],"(IPD)":[142],"outcomes":[145,177],"derived":[147],"digitized":[149],"Kaplan-Meier":[150],"(KM)":[151],"curves":[153,174,187],"then":[154],"pooled":[155,212],"analyzed":[157],"using":[158],"KM":[159,173,186],"methods.":[160],"Results:":[161],"Fifteen":[162],"(717":[164],"patients)":[165],"that":[168,233,259],"reported":[169,215],"median,":[170],"landmark,":[171],"without":[184],"obtained":[191],"6":[193],"arms":[194],"(3":[195],"nilotinib":[196],"and/or":[197],"dasatinib;":[198],"other":[200],"TKIs).":[201],"based":[209],"on":[210],"IPD":[213],"is":[214,271],"Table.":[218],"To":[219],"avoid":[220],"confounding":[221,291],"post-progression":[225],"1":[229],"excluded":[232],"included":[234],"follow-up":[235],"after":[236],"date":[238],"ponatinib\u2019s":[240],"approval.":[241],"Conclusions:":[242],"EstimatedOS":[243],"appears":[254],"shorter":[257],"than":[258,273],"observed":[260],"among":[261],"ponatinib-treated":[262],"PACE:":[265],"4-year":[266],"probability":[268,277],"higher":[272],"2-year":[275],"Further":[281],"analyses":[282],"are":[283],"needed":[284],"identify":[286],"adjust":[288],"potentially":[290],"factors.":[292],"[Table:":[293],"see":[294],"text]":[295]},"counts_by_year":[],"updated_date":"2026-07-14T23:27:15.235271","created_date":"2018-09-27T00:00:00"}